Search the Newsreel

Stifel raises LB Pharmaceuticals stock price target on pipeline outlook

Stifel has raised its price target for LB Pharmaceuticals Inc (NASDAQ:LBRX) shares to $53 from $40, maintaining a Buy rating, citing expanded indication plans for its lead compound LB-102 in Alzheimer’s and schizophrenia. The company is conducting a phase 3 study for LB-102 with …

BMO Capital Markets Increases LB Pharmaceuticals (NASDAQ:LBRX) Price Target to $54.00

BMO Capital Markets has raised its price target for LB Pharmaceuticals (NASDAQ:LBRX) to $54.00 from $46.00, maintaining an "outperform" rating, which suggests a 19.13% upside. Despite this, the company reported a quarterly loss of $1.71 per share, missing the consensus estimate of $0.84. LB …

LB Pharmaceuticals Inc Stock 12‑Month Price Target Raised to $47.67, Implies 4% Upside

The average 12-month price target for LB Pharmaceuticals Inc stock has been raised from $45.73 to $47.67 by 9 analysts, implying a 4% potential upside from the August 10 closing price. The consensus rating for LBRX remains a "Buy" from all covering analysts. Investors …

LB Pharmaceuticals Releases Q2 2026 Financial Results

LB Pharmaceuticals (LBRX) reported its Q2 2026 financial results, showing a net loss of $51.6 million and a loss per share of $1.71. This represents an 87.4% improvement compared to Q2 2025, driven by advancements in its neuropsychiatric disease pipeline. Analysts maintain a bullish …

LB PHARMACEUTICALS INC Q2 2026: Revenue $0 Net loss $(51.6M), EPS $(1.71) — 10-Q Summary

LB PHARMACEUTICALS INC (LBRX) reported a net loss of $(51.6M) and diluted loss per share of $(1.71) for Q2 2026, with no product revenue. This compares to a net loss of $(4.9M) and diluted EPS of $(13.58) in Q2 2025. The company highlighted pipeline …

LB Pharmaceuticals Inc.: Q2 Earnings Snapshot

LB Pharmaceuticals Inc. (LBRX) reported a second-quarter loss of $51.6 million, or $1.71 per share, missing Wall Street expectations. Analysts surveyed by Zacks Investment Research had estimated a loss of 84 cents per share. The report was generated by Automated Insights using data from …

LB Pharmaceuticals Q2 Loss Per Share Narrows

LB Pharmaceuticals Inc. announced its Q2 2026 earnings results, reporting a narrower loss per share compared to estimates. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapies for neuropsychiatric diseases, with its lead product candidate LB-102 currently in Phase III for schizophrenia.

LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages

LB Pharmaceuticals Inc (NASDAQ:LBRX) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $45.13, closely aligning with its current trading price of $45.03. Recent analyst coverage, including BMO Capital Markets and HC Wainwright, has been largely …

HC Wainwright Issues Optimistic Estimate for LBRX Earnings

HC Wainwright has updated its Q3 2026 EPS estimate for LB Pharmaceuticals (NASDAQ:LBRX) to a loss of $0.95 per share, an improvement from its previous forecast. The firm maintained its "Buy" rating and a $45 price target, aligning with the consensus "Moderate Buy" rating …

Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX)

Analysts have provided insights on Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX), and SpaceX (SPCX). H.C. Wainwright reiterated a Hold rating for Evommune, while Piper Sandler maintained a Buy rating for LB Pharmaceuticals with a $78.00 price target. RBC Capital also kept a Buy …

LB Pharmaceuticals (LBRX) holder acquires 286K pre-funded warrants

Deep Track Biotechnology Master Fund, Ltd., a ten percent holder of LB Pharmaceuticals (LBRX), purchased 286,205 pre-funded warrants to buy LBRX common stock at $34.9399 per warrant on July 30, 2026. This transaction increased its direct pre-funded warrant position to 664,649. These warrants are …

Form 4 LB Pharmaceuticals Inc For: 3 August By Investing.com

This article reports on a Form 4 filing for LB Pharmaceuticals Inc. for August 3rd. Form 4 filings are regulatory documents submitted to the SEC by company insiders, indicating changes in their ownership of company stock. The article itself is brief, essentially serving as …

Piper Sandler reiterates Overweight on LB Pharmaceuticals stock

Piper Sandler has reiterated an Overweight rating and a $78.00 price target for LB Pharmaceuticals (NASDAQ:LBRX), citing the company's strong financial position and promising drug pipeline. The stock has surged significantly over the past year, and the firm highlights upcoming clinical trial data for …

Price to earnings forward of LB Pharmaceuticals Inc – NASDAQ:LBRX

This article provides financial information for LB Pharmaceuticals Inc (NASDAQ:LBRX), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content is primarily a data placeholder on TradingView, detailing various products, community features, and company …

LB Pharmaceuticals (NASDAQ:LBRX) Hits New 12-Month High - Still a Buy?

LB Pharmaceuticals (NASDAQ:LBRX) recently hit a new 52-week high of $41.71, trading up 7.7% and giving the company a market capitalization of $1.24 billion. Analyst sentiment is largely positive, with a "Moderate Buy" consensus and price targets ranging from $45 to $46. The clinical-stage …

LB Pharmaceuticals (NASDAQ:LBRX) Receives "Buy" Rating from HC Wainwright

Enterprise value to revenue forward of LB Pharmaceuticals Inc – NASDAQ:LBRX

This article provides financial information for LB Pharmaceuticals Inc (NASDAQ:LBRX) regarding its enterprise value to revenue forward. It appears to be a snapshot of financial data from TradingView, focusing on the company's valuation metrics within the Pharmaceuticals sector.

LB Pharmaceuticals Inc Revenue Breakdown – BOATS:LBRX

The article provides a high-level overview of LB Pharmaceuticals Inc. (LBRX) on TradingView, focusing on its financial data. It lists various sections available for the company, such as overview, financials, documents, news, community, forecasts, seasonals, and ETFs. The content primarily acts as a navigation …

Stempoint Capital LP Takes $1.23 Million Position in LB Pharmaceuticals Inc $LBRX

Stempoint Capital LP has acquired a new position in LB Pharmaceuticals Inc. (NASDAQ:LBRX), purchasing 50,000 shares valued at approximately $1.23 million, representing 0.17% of the company. Several other institutional investors also established new positions. Analysts currently have a "Moderate Buy" consensus rating for LB …

LB Pharmaceuticals raises USD 150m to expand LB-102 into three neuropsychiatric indications

LB Pharmaceuticals Inc. recently completed a $150 million private placement to expand its lead asset, LB-102, into two new neuropsychiatric indications: negative symptoms of schizophrenia and Alzheimer's disease agitation and psychosis. This funding supports the ongoing pivotal Phase III schizophrenia trial, with topline results …

LB Pharmaceuticals Announces $150 Million Private Placement

LB Pharmaceuticals Inc. has announced a private placement to sell shares of its common stock and pre-funded warrants to institutional investors, expected to generate approximately $150 million in gross proceeds. The company plans to use these funds for pipeline expansion of LB-102 into new …

LB Pharmaceuticals Prices ~$150 Million Private Placement of Stock and Pre-Funded Warrants

LB Pharmaceuticals has secured approximately $150 million through a private placement of common shares and pre-funded warrants. The funds will primarily support the expansion of its drug candidate LB-102 into new indications, including potential trials for schizophrenia and Alzheimer's disease-related conditions, as well as …

LB Pharmaceuticals raises $150M in private placement By Investing.com

LB Pharmaceuticals Inc (NASDAQ:LBRX) has secured approximately $150 million in gross proceeds through a private placement of common stock and pre-funded warrants to institutional investors. The company plans to use the funds to expand its LB-102 pipeline into new indications, including symptoms of schizophrenia …

LB Pharmaceuticals Plans $150M Raise for LB-102 Expansion

LB Pharmaceuticals announced a private placement to raise approximately $150 million before expenses through the sale of common shares and pre-funded warrants. The proceeds will be used to fund the pipeline expansion of LB-102 into new indications, including negative symptoms of schizophrenia and Alzheimer’s …

Biotech Stocks At 52-Week Highs - INCY Rises With Q2 Results, PLSE, SI, BVS, LBRX

Several biotech stocks, including Incyte Corporation (INCY), Pulse Biosciences Inc. (PLSE), Shoulder Innovations Inc. (SI), Bioventus Inc. (BVS), and LB Pharmaceuticals Inc. (LBRX), reached 52-week highs on July 28, 2026. These gains were primarily driven by positive quarterly financial results and promising advancements in …

LB Pharmaceuticals Secures $150 Million via Private Placement to Advance LB-102 Pipeline Expansion

LB Pharmaceuticals Inc (NASDAQ: LBRX) has secured approximately $150 million through a private placement of common stock and pre-funded warrants. This funding will be used to expand the pipeline for its lead candidate, LB-102, into new indications such as negative symptoms of schizophrenia and …

Eversept Partners LP Makes New $2.47 Million Investment in LB Pharmaceuticals Inc $LBRX

Eversept Partners LP has made a new investment of $2.47 million in LB Pharmaceuticals Inc (NASDAQ:LBRX), acquiring 100,198 shares, representing a 0.35% stake in the company. This investment comes as several other institutional investors have also initiated positions in LB Pharmaceuticals. Despite the company …

LBRX|LB Pharmaceuticals Inc|Price:35.010|Chg%:+0.390

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric diseases, including schizophrenia and bipolar depression. Their lead product candidate, LB-102, is a Phase III-ready oral medication for acute schizophrenia, and they are also developing a long-acting injectable formulation. As …

LB Pharmaceuticals Inc (LBRX) Institutional Confidence

This article from TradingKey provides an overview of institutional confidence in LB Pharmaceuticals Inc (LBRX). It lists key institutional shareholders and their shareholdings, highlighting changes in some major positions. The data indicates recent activity from institutional investors in LBRX.

H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $45

H.C. Wainwright has reiterated its Buy rating on L.B. Pharmaceuticals (LBRX.US) stock, maintaining a price target of $45. This suggests continued confidence from the firm in the company's prospects. Investors may view this as a positive signal regarding LBRX.US's future performance.

LB Pharmaceuticals Inc $LBRX is Spruce Street Capital LP's 3rd Largest Position

Spruce Street Capital LP significantly increased its stake in LB Pharmaceuticals (NASDAQ:LBRX) during the first quarter, making it their third-largest holding. Wall Street analysts maintain a "Moderate Buy" consensus for LBRX, with an average price target of $40.43, following several positive initiations and reaffirmations. …

Enterprise value to revenue forward of LB Pharmaceuticals Inc – BOATS:LBRX

This page from TradingView provides financial information for LB Pharmaceuticals Inc (LBRX) on the Blue Ocean Alternative Trade System (BOATS). It shows the enterprise value to revenue forward for the company, indicating key financial data for investors. The page is an overview of the …

H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock

H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for LB Pharmaceuticals (NASDAQ:LBRX) after the company announced an accelerated timeline for its pivotal Phase 3 schizophrenia drug trial. The firm anticipates earlier regulatory submission and market entry for LB-102 due to …